Testosterone has become one of the most heavily marketed subjects in men’s health. Fatigue, reduced motivation, weight gain, difficulty building muscle, and diminished libido are frequently attributed to “low T,” while online clinics promise convenient testing and prescriptions without an in-person appointment.
There is credible evidence that testosterone concentrations have declined among American men over time. There is also evidence of substantially increased testosterone use among reproductive-age men. Neither finding, however, means that every tired or overweight man has testosterone deficiency—or that testosterone replacement therapy (TRT) is necessarily the appropriate first response.
Understanding the difference requires looking beyond a single laboratory result.
One of the most frequently cited investigations used data from the Massachusetts Male Aging Study. Researchers compared similarly aged men examined between 1987 and 2004 and found an age-independent decline in total testosterone of approximately 1.2% per year. The decline persisted after adjustment for obesity, smoking, medication use, and other measured health and lifestyle factors (Travison et al., 2007).
A later analysis of nationally representative NHANES data also reported declining total testosterone concentrations among American adolescent and young-adult males ages 15–39 between 1999 and 2016. The trend remained significant after adjustment for age, race, body mass index, chronic disease, smoking, alcohol consumption, and physical activity (Lokeshwar et al., 2021).
These findings support a population-level downward trend, but they do not establish a single causal mechanism. Testosterone measurement methods changed during the NHANES study period, and cross-sectional surveys compare different populations rather than tracking the same individuals longitudinally. Increasing obesity, insulin resistance, diabetes, sleep disruption, medication use, chronic illness, and declining metabolic health likely explain part of the trend. Environmental influences, including endocrine-disrupting chemicals, remain under investigation and may be considered plausible contributing factors.
Low testosterone may also be a consequence—not merely a cause—of poor health. Obesity and metabolic dysfunction can suppress hypothalamic–pituitary–gonadal signaling, creating a bidirectional cycle in which worsening metabolic health and lower androgen activity reinforce one another.
Testosterone prescribing increased dramatically during the early 2000s. An analysis of commercially insured American men ages 18–45 found that testosterone use increased fourfold between 2003 and 2013, from 29.2 to 118.1 users per 10,000 person-years. Use increased more rapidly in this reproductive-age group than among men ages 56–64, with approximately three-quarters of younger users aged 35–45 (Rao et al., 2017).
The longer national trend is not a simple, uninterrupted rise. Overall U.S. prescribing peaked around 2013 and subsequently declined following increased regulatory scrutiny and safety concerns (Baillargeon et al., 2018). However, direct-to-consumer telehealth platforms have created a new access pathway for testosterone and related hormone-modifying therapies.
Precise national data on how much current TRT growth is driven by online prescribing—particularly among men under 40—remain limited. A recent convenience survey of 401 American men ages 18–40 found that 39.9% had considered testosterone-boosting products or medications and 13.5% reported using androgen-related therapies. Because this was a self-selected sample, it should not be interpreted as population prevalence (Aguiar et al., 2024).
The most accurate conclusion is that demand, marketing, and access have expanded rapidly, while surveillance of the online prescribing ecosystem has not kept pace.
Online programs often begin with a symptom questionnaire and a laboratory panel including total testosterone, free testosterone, SHBG, estradiol, CBC, metabolic panel, and PSA.
The issue is not telemedicine itself. The issue arises when nonspecific symptoms and a single laboratory value are treated as sufficient for diagnosing hypogonadism.
Testosterone follows a diurnal rhythm, peaking in the morning. Levels may also be transiently suppressed by poor sleep, acute illness, caloric restriction, heavy training, certain medications, or recent energy intake. For this reason, clinical guidelines recommend diagnosing hypogonadism only when symptoms are present and testosterone is consistently low on at least two separate morning measurements (Bhasin et al., 2018; Mulhall et al., 2018).
A “secret shopper” study of seven U.S. direct-to-consumer testosterone platforms found that most would prescribe testosterone to a 34-year-old man with normal laboratory values and nonspecific symptoms. Only one platform assessed fertility goals or cardiovascular history, and several failed to adequately address risks such as infertility or erythrocytosis (Dubin et al., 2022).
Interpretation also depends on context. A value within the laboratory reference range may still be low for a young, healthy man, while a below-average value does not automatically indicate disease. Clinical interpretation requires integrating symptoms, repeat testing, SHBG, pituitary hormones, metabolic health, medications, sleep, and fertility goals.
The push to establish well-validated “functional medicine” testosterone ranges to supplant established diagnostic criteria is still a work in progress. However, a meaningful evaluation focuses on physiology and underlying causes rather than alternative cutoffs.
Depending on clinical context, evaluation may include:
Additional hormones such as DHEA-S, cortisol, or DHT are not routinely required unless specific clinical indications exist.
The most immediate concern is fertility. Exogenous testosterone suppresses hypothalamic and pituitary signaling, reducing intratesticular testosterone and sperm production, sometimes to the level of azoospermia. Recovery after discontinuation is variable and may take months (Rao et al., 2017; Naelitz et al., 2025).
Other potential adverse effects include increased hematocrit, acne, fluid retention, breast symptoms, and elevated blood pressure, all of which require ongoing monitoring (Bhasin et al., 2018; Mulhall et al., 2018).
The TRAVERSE trial found no increase in major cardiovascular events in appropriately selected older men with confirmed hypogonadism, but did observe higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury (Lincoff et al., 2023). These findings should not be extrapolated to healthy young men using testosterone for performance or nonspecific symptoms.
In 2025, the FDA removed the boxed warning for heart attack and stroke but emphasized blood pressure risk across testosterone products (FDA, 2025).
A large body of evidence supports the idea that testosterone is highly sensitive to energy balance, metabolic health, sleep quality, exercise modality, and environmental exposures. Importantly, these interventions tend to improve endogenous hormonal regulation rather than simply “boosting” serum testosterone in isolation.
The most robust and reproducible intervention for increasing testosterone in overweight and obese men is fat loss, particularly when it improves insulin sensitivity.
A meta-analysis of weight loss interventions found that reductions in body fat are consistently associated with increases in total and free testosterone, with the magnitude of improvement proportional to the degree of weight loss (Corona et al., 2013). Mechanistically, adipose tissue contributes to aromatization of testosterone to estradiol and suppresses hypothalamic–pituitary signaling via inflammatory and insulin-mediated pathways.
Among exercise interventions, progressive resistance training shows the most reliable association with improved androgen status, particularly in previously sedentary men.
A systematic review and meta-analysis found that resistance training can increase resting testosterone modestly in some populations, with stronger effects seen in:
However, in already healthy, eugonadal men, long-term resting testosterone changes are often small, suggesting that the primary benefit is improved androgen sensitivity, body composition, and insulin signaling, rather than large sustained hormonal elevation.
HIIT has been shown to acutely increase testosterone and improve insulin sensitivity, particularly in men with metabolic dysfunction.
Studies suggest that short bursts of high-intensity exercise (e.g., 30–60 second sprints with recovery intervals) improve:
These effects are most pronounced when HIIT replaces sedentary behavior rather than being added to already high training loads.
Sleep restriction is one of the most reproducible suppressors of testosterone.
Experimental studies show that reducing sleep to ~5 hours per night for one week reduces daytime testosterone by 10–15% in healthy young men (Leproult & Van Cauter, 2011). Sleep apnea is also strongly associated with reduced testosterone independent of obesity.
Restoration of:
is associated with normalization of gonadal signaling in many cases.
Diet influences testosterone primarily through energy availability, fat mass regulation, and micronutrient status.
Key findings include:
Intermittent fasting (IF) and time-restricted eating (TRE) show mixed but context-dependent effects.
A systematic review suggests that hormonal outcomes depend heavily on whether fasting leads to sustained energy deficit or improved metabolic flexibility (Templeman et al., 2020).
Micronutrients do not “boost” testosterone above physiological range in replete individuals, but correcting deficiencies is important.
Emerging evidence links certain environmental exposures to altered androgen signaling.
Associations have been reported between lower testosterone and exposure to:
These compounds may act through oxidative stress, Leydig cell dysfunction, and hypothalamic disruption (Meeker, 2010; Hauser & Calafat, 2005).
While causality in humans is complex, practical exposure-reduction strategies include:
Chronic alcohol intake is consistently associated with reduced testosterone via:
Even moderate-to-heavy intake can reduce gonadal signaling over time (Emanuele & Emanuele, 1998).
The central issue is not simply whether testosterone is “low,” but whether symptoms reflect true hypogonadism or reversible metabolic, lifestyle, or medical contributors.
TRT is appropriate when deficiency is clearly established—but not as a shortcut for nonspecific symptoms or convenience-based prescribing.
Biospec Nutritionals — Medical & Educational Disclaimer
This content is provided for educational and informational purposes only and is not intended to provide medical advice, diagnosis, or treatment. It is not a substitute for individualized guidance from a qualified healthcare professional. Always consult your physician or other qualified healthcare provider before starting, stopping, or changing any supplement, medication, diet, or exercise program.
† FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Aguiar J, Greenberg D, Halpern J, Brannigan R, Dubin J. Utilization patterns of testosterone supplementation and replacement in young adult men. Journal of Sexual Medicine. 2024.
Baillargeon J, Kuo YF, Westra JR, Urban RJ, Goodwin JS. Testosterone prescribing in the United States, 2002–2016. JAMA. 2018;320(2):200–202.
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715–1744.
Boutcher SH. High-intensity intermittent exercise and fat loss. Journal of Obesity. 2011.
Cinar V, Polat Y, Baltaci AK, Mogulkoc R. Effects of magnesium supplementation on testosterone levels. Biological Trace Element Research. 2011.
Corona G, Rastrelli G, Monami M, et al. Body weight loss reverses obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology. 2013;168(6):829–843.
D’Andrea S, Spaggiari G, Barbonetti A, Santi D. Vitamin D supplementation and testosterone: systematic review and meta-analysis of randomized controlled trials. 2026.
Dubin JM, Jesse E, Fantus RJ, et al. Guideline-discordant care among direct-to-consumer testosterone therapy platforms. JAMA Internal Medicine. 2022;182(12):1321–1323.
Emanuele MA, Emanuele NV. Alcohol’s effects on male reproduction. Alcohol Health & Research World. 1998.
FDA. Testosterone products: labeling changes and blood pressure warning update. 2025.
Hackney AC. Effects of HIIT on endocrine function. Sports Medicine. 2020.
Hauser R, Calafat AM. Phthalates and human health. Environmental Health Perspectives. 2005.
Hayes LD, Bickerstaff GF, Baker JS. Interactions of resistance training and testosterone. Sports Medicine. 2019.
Kraemer WJ, Ratamess NA. Hormonal responses to resistance exercise. Sports Medicine. 2005.
Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. 2011;305(21):2173–2174.
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine. 2023;389(2):107–117.
Lokeshwar SD, Patel P, Fantus RJ, et al. Decline in serum testosterone levels among adolescent and young adult men in the USA. European Urology Focus. 2021;7(4):886–889.
Meeker JD. Environmental exposure and male reproductive hormones. Environmental Health Perspectives. 2010.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology. 2018;200(2):423–432.
Naelitz BD, Momtazi-Mar L, Vallabhaneni S, et al. Testosterone replacement therapy and spermatogenesis in reproductive-age men. Nature Reviews Urology. 2025.
Potter NJ, Tomkinson GR, Dufner TJ, et al. Effects of exercise training on resting testosterone concentrations: systematic review and meta-analysis. Journal of Strength and Conditioning Research. 2021;35(12):3521–3528.
Prasad AS et al. Zinc deficiency and hypogonadism. Nutrition. 1996.
Rao PK, Boulet SL, Mehta A, et al. Trends in testosterone replacement therapy use among reproductive-age men in the United States. Journal of Urology. 2017;197(4):1121–1126.
Templeman I, Gonzalez JT, Thompson D, Betts JA. Intermittent fasting and metabolic health. British Journal of Nutrition. 2020.
Travison TG, Araujo AB, O’Donnell AB, Kupelian V, McKinlay JB. A population-level decline in serum testosterone levels in American men. Journal of Clinical Endocrinology & Metabolism. 2007;92(1):196–202.
Whittaker J, Wu H. Dietary fat and testosterone: systematic review. Journal of Steroid Biochemistry and Molecular Biology. 2021.